Literature DB >> 14672901

Fas gene promoter polymorphisms in primary Sjögren's syndrome.

C G Mullighan1, S Heatley, S Lester, M Rischmueller, T P Gordon, P G Bardy.   

Abstract

BACKGROUND: Fas mediated apoptosis may be important in the pathogenesis of primary Sjögren's syndrome (pSS).
OBJECTIVE: To examine genetic variation in the promoter region of the Fas gene in pSS.
METHODS: Two single nucleotide polymorphisms at positions -1377(G/A) and -670(G/A) in the Fas gene promoter were genotyped by PCR-SSP in 101 patients with pSS and 108 Caucasoid controls.
RESULTS: No significant differences in allele or genotype frequencies were detected between the patients with pSS and controls. However, significant associations were observed with Ro/La autoantibody negative patients, who display milder and later onset disease. The -670A allele was more frequent in Ro/La autoantibody negative patients than in Ro/La autoantibody positive patients (p = 0.04).
CONCLUSION: This study does not confirm an earlier report of an association between pSS and the Fas promoter -670G allele. However, the results suggest that genetically determined variability in Fas expression may modulate Ro/La autoantibody responses in patients with pSS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14672901      PMCID: PMC1754724          DOI: 10.1136/ard.2003.006056

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  11 in total

Review 1.  Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care.

Authors:  J Sieper; M Rudwaleit
Journal:  Ann Rheum Dis       Date:  2004-11-04       Impact factor: 19.103

2.  Associations between the FAS -670 A/G and -1,377 G/A polymorphisms and susceptibility to autoimmune rheumatic diseases: a meta-analysis.

Authors:  Young Ho Lee; Sang-Cheol Bae; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Mol Biol Rep       Date:  2012-10-05       Impact factor: 2.316

3.  Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.

Authors:  X Baraliakos; J Listing; M Rudwaleit; J Brandt; J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

Review 4.  Psoriatic arthritis treatment: biological response modifiers.

Authors:  P J Mease; C E Antoni
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 5.  How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?

Authors:  J Sieper; M Rudwaleit
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 6.  Genes and Sjögren's syndrome.

Authors:  Beth L Cobb; Christopher J Lessard; John B Harley; Kathy L Moser
Journal:  Rheum Dis Clin North Am       Date:  2008-11       Impact factor: 2.670

7.  APO-1/Fas gene: Structural and functional characteristics in systemic lupus erythematosus and other autoimmune diseases.

Authors:  Richa Singh; Vandana Pradhan; Manisha Patwardhan; K Ghosh
Journal:  Indian J Hum Genet       Date:  2009-09

8.  EGF activates PI3K-Akt and NF-kappaB via distinct pathways in salivary epithelial cells in Sjögren's syndrome.

Authors:  Hideki Nakamura; Atsushi Kawakami; Hiroaki Ida; Takehiko Koji; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2007-07-20       Impact factor: 2.631

Review 9.  Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

Authors:  Sujani Yadlapati; Petros Efthimiou
Journal:  Biomed Res Int       Date:  2016-06-27       Impact factor: 3.411

10.  FAS promoter polymorphisms and serum sFas level are associated with increased risk of nerve damage in Bangladeshi patients with Guillain-Barré syndrome.

Authors:  Zhahirul Islam; Israt Jahan; Rijwan U Ahammad; Mohammad Shahnaij; Shamsun Nahar; Quazi D Mohammad
Journal:  PLoS One       Date:  2018-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.